Natalizumab concentrations during pregnancy in three patients with multiple sclerosis

被引：2

作者：

Toorop, Alyssa A. ^{[1
]}

Rispens, Theo ^{[2
,3
,4
]}

Strijbis, Eva M. M. ^{[1
]}

van Oosten, Bob W. ^{[1
]}

de Jong, Brigit A. ^{[1
]}

Uitdehaag, Bernard M. J. ^{[1
]}

Killestein, Joep ^{[1
]}

van Kempen, Zoe L. E. ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, Univ Amsterdam, MS Ctr Amsterdam, Dept Neurol,Med Ctr,Amsterdam Neurosci, Amsterdam, Netherlands

[2] Sanquin Res, Dept Immunopathol, Amsterdam, Netherlands

[3] Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, Amsterdam, Netherlands

[4] Sanquin Diagnost Serv, Biol Lab, Amsterdam, Netherlands

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 02期

关键词：

Multiple sclerosis; natalizumab; personalized dosing; extended interval dosing; pregnancy; concentrations;

D O I：

10.1177/13524585211052168

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

In women with very active multiple sclerosis (MS), natalizumab can be continued during pregnancy to prevent rebound disease activity. Our aim was to evaluate changes in serum natalizumab trough concentrations during pregnancy. Blood samples of 3 patients were collected before, during, and after pregnancy. Natalizumab trough concentrations gradually decreased during pregnancy. The patient with the lowest trough concentrations during the third trimester was treated with extended interval dosing (EID). After delivery, natalizumab concentrations increased to similar levels as before pregnancy. All patients remained clinically and radiologically stable. MS neurologists should be aware of decreasing natalizumab concentrations during pregnancy, especially in patients with low initial trough concentrations and patients with EID.

引用

页码：323 / 326

页数：4

共 10 条

[1] Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis [J].

Demortiere, Sarah ;

Rico, Audrey ;

Maarouf, Adil ;

Boutiere, Clemence ;

Pelletier, Jean ;

Audoin, Bertrand .

MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (05) :712-718

[2] Pharmacokinetics of drugs in pregnancy [J].

Feghali, Maisa ;

Venkataramanan, Raman ;

Caritis, Steve .

SEMINARS IN PERINATOLOGY, 2015, 39 (07) :512-519

[3] Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure [J].

Flanagan, Emma ;

Gibson, Peter R. ;

Wright, Emily K. ;

Moore, Gregory T. ;

Sparrow, Miles P. ;

Connell, William ;

Kamm, Michael A. ;

Begun, Jakob ;

Christensen, Britt ;

De Cruz, Peter ;

Shelton, Edward ;

Dowling, Damian ;

Andrews, Jane M. ;

Brown, Steven J. ;

Niewiadomski, Olga ;

Ward, Mark G. ;

Rosella, Ourania ;

Rosella, Gennaro ;

Kiburg, Katerina V. ;

Ross, Alyson L. ;

Bell, Sally J. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (10) :1551-1562

[4] Natalizumab Use During the Third trimester of Pregnancy [J].

Haghikia, Aiden ;

Langer-Gould, Annette ;

Rellensmann, Georg ;

Schneider, Henriette ;

Tenenbaum, Tobias ;

Elias-Hamp, Birte ;

Menck, Sylvia ;

Zimmermann, Julian ;

Herbstritt, Sandra ;

Marziniak, Martin ;

Kuempfel, Tania ;

Meinl, Ingrid ;

Plavina, Tatiana ;

Gold, Ralf ;

Hellwig, Kerstin .

JAMA NEUROLOGY, 2014, 71 (07) :891-895

[5] Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function [J].

Khatri, B. O. ;

Man, S. ;

Giovannoni, G. ;

Koo, A. P. ;

Lee, J. -C. ;

Tucky, B. ;

Lynn, F. ;

Jurgensen, S. ;

Woodworth, J. ;

Goelz, S. ;

Duda, P. W. ;

Panzara, M. A. ;

Ransohoff, R. M. ;

Fox, R. J. .

NEUROLOGY, 2009, 72 (05) :402-409

[6]

Polman Chris H, 2006, N Engl J Med, V354, P899

[7] Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks [J].

Portaccio, Emilio ;

Moiola, Lucia ;

Martinelli, Vittorio ;

Annovazzi, Pietro ;

Ghezzi, Angelo ;

Zaffaroni, Mauro ;

Lanzillo, Roberta ;

Morra, Vincenzo Brescia ;

Rinaldi, Francesca ;

Gallo, Paolo ;

Tortorella, Carla ;

Paolicelli, Damiano ;

Pozzilli, Carlo ;

De Giglio, Laura ;

Cavalla, Paola ;

Cocco, Eleonora ;

Marrosu, Maria Giovanna ;

Solaro, Claudio ;

Uccelli, Antonio ;

Laroni, Alice ;

Pasto, Luisa ;

Giannini, Marta ;

Trojano, Maria ;

Comi, Giancarlo ;

Amato, Maria Pia .

NEUROLOGY, 2018, 90 (10) :E832-E839

[8] Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody [J].

Rispens, Theo ;

van Leeuwen, Astrid ;

Vennegoor, Anke ;

Killestein, Joep ;

Aalberse, Rob C. ;

Wolbink, Gerrit J. ;

Aarden, Lucien A. .

ANALYTICAL BIOCHEMISTRY, 2011, 411 (02) :271-276

[9] Personalized extended interval dosing of natalizumab in MS A prospective multicenter trial [J].

van Kempen, Zoe L. E. ;

Hoogervorst, Erwin L. J. ;

Wattjes, Mike P. ;

Kalkers, Nynke F. ;

Mostert, Jop P. ;

Lissenberg-Witte, Birgit I. ;

de Vries, Annick ;

ten Brinke, Anja ;

van Oosten, Bob W. ;

Barkhof, Frederik ;

Teunissen, Charlotte E. ;

Uitdehaag, Bernard M. J. ;

Rispens, Theo ;

Killestein, Joep .

NEUROLOGY, 2020, 95 (06) :E745-E754

[10] Pharmacodynamics of natalizumab extended interval dosing in MS [J].

Zhovtis Ryerson, Lana ;

Li, Xiaochun ;

Goldberg, Judith D. ;

Hoyt, Tamara ;

Christensen, Angel ;

Metzger, Ryan R. ;

Kister, Ilya ;

Foley, John .

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (02)

← 1 →